Verity Asset Management Inc. Takes $174,000 Position in Eli Lilly and Company (NYSE:LLY)

Verity Asset Management Inc. bought a new position in Eli Lilly and Company (NYSE:LLYGet Rating) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,047,402 shares of the company’s stock, valued at approximately $174,000. Verity Asset Management Inc. owned approximately 0.11% of Eli Lilly and as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of LLY. McLean Asset Management Corp lifted its position in shares of Eli Lilly and by 2.4% during the 1st quarter. McLean Asset Management Corp now owns 1,405 shares of the company’s stock valued at $402,000 after buying an additional 33 shares during the last quarter. Affiance Financial LLC lifted its holdings in Eli Lilly and by 1.9% in the 1st quarter. Affiance Financial LLC now owns 1,835 shares of the company’s stock worth $525,000 after buying an additional 35 shares during the period. Ashfield Capital Partners LLC raised its position in shares of Eli Lilly and by 0.5% in the 1st quarter. Ashfield Capital Partners LLC now owns 7,975 shares of the company’s stock worth $2,284,000 after acquiring an additional 36 shares in the last quarter. American Money Management LLC increased its position in Eli Lilly and by 0.8% during the 1st quarter. American Money Management LLC now owns 4,759 shares of the company’s stock valued at $1,363,000 after buying an additional 36 shares in the last quarter. Finally, Journey Strategic Wealth LLC increased its holdings in shares of Eli Lilly and by 2.3% in the 1st quarter. Journey Strategic Wealth LLC now owns 1,673 shares of the company’s stock worth $479,000 after purchasing an additional 37 shares in the last quarter. Institutional investors own 82.45% of the company’s stock.

Eli Lilly and Stock Performance

Shares of LLY opened at $309.47 on Friday. The company’s 50 day moving average price is $316.93 and its 200 day moving average price is $302.40. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.85 and a current ratio of 1.10. Eli Lilly and Company has a 52 week low of $220.20 and a 52 week high of $335.33. The company has a market capitalization of $294.05 billion, a PE ratio of 49.36, a PEG ratio of 1.98 and a beta of 0.38.

Eli Lilly and (NYSE:LLYGet Rating) last announced its earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The company had revenue of $6.49 billion for the quarter, compared to analyst estimates of $6.85 billion. During the same quarter last year, the business posted $1.87 earnings per share. The business’s quarterly revenue was down 3.7% on a year-over-year basis. Research analysts expect that Eli Lilly and Company will post 7.97 EPS for the current fiscal year.

Eli Lilly and Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 9th. Shareholders of record on Monday, August 15th were paid a $0.98 dividend. This represents a $3.92 annualized dividend and a yield of 1.27%. The ex-dividend date of this dividend was Friday, August 12th. Eli Lilly and’s dividend payout ratio (DPR) is presently 62.52%.

Insider Buying and Selling at Eli Lilly and

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction on Wednesday, June 22nd. The stock was sold at an average price of $306.84, for a total transaction of $64,436,400.00. Following the completion of the transaction, the insider now owns 104,623,810 shares in the company, valued at approximately $32,102,769,860.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction dated Wednesday, June 22nd. The stock was sold at an average price of $306.84, for a total transaction of $64,436,400.00. Following the transaction, the insider now directly owns 104,623,810 shares of the company’s stock, valued at approximately $32,102,769,860.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Alonzo Weems sold 656 shares of the firm’s stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total value of $199,752.00. Following the transaction, the senior vice president now directly owns 8,136 shares in the company, valued at $2,477,412. The disclosure for this sale can be found here. Over the last three months, insiders have sold 753,125 shares of company stock valued at $242,744,201. 0.12% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on LLY. Morgan Stanley raised their price target on Eli Lilly and from $395.00 to $412.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 7th. BMO Capital Markets boosted their price objective on Eli Lilly and from $369.00 to $396.00 and gave the company an “outperform” rating in a research report on Tuesday, September 6th. UBS Group boosted their price objective on Eli Lilly and to $335.00 and gave the company an “outperform” rating in a research report on Wednesday, July 27th. SVB Leerink initiated coverage on Eli Lilly and in a report on Monday, May 23rd. They issued an “outperform” rating and a $341.00 target price on the stock. Finally, StockNews.com raised Eli Lilly and from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Eli Lilly and currently has an average rating of “Moderate Buy” and a consensus price target of $330.44.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.